Related Experiment Video
Updated: Jun 21, 2025
07:22
Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
2.9K
Bacteriophage therapy and infective endocarditis - is it realistic?
Emilie C Pedersen1, Christian Johann Lerche1,2, Franziska Angelica Schwartz1
1Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.
Summary
Bacteriophage therapy shows promise for treating infective endocarditis (IE), a severe heart infection with high mortality. Further research is needed to confirm its safety and efficacy against antibiotic-resistant bacteria in biofilms.
Area of Science:
- Cardiology
- Infectious Diseases
- Microbiology
Background:
- Infective endocarditis (IE) is a life-threatening heart infection with persistently high mortality rates.
- Current treatments struggle against antibiotic-tolerant bacterial biofilms within heart vegetations, especially with rising antibiotic resistance.
- Novel therapeutic strategies are crucial to improve outcomes for patients with infective endocarditis.
Purpose of the Study:
- To review the potential of bacteriophage therapy as a treatment for infective endocarditis (IE).
- To assess the feasibility of using bacteriophages to combat biofilm-associated infections in IE.
- To identify knowledge gaps regarding bacteriophage therapy's safety and efficacy in IE.
Main Methods:
- Literature review of existing preclinical and clinical studies on bacteriophage therapy for IE.
- Analysis of bacteriophage mechanisms against bacterial biofilms relevant to endocarditis.
- Evaluation of challenges and future directions for implementing phage therapy in IE.
Main Results:
- Bacteriophage therapy is a reemerging strategy for biofilm-associated infections caused by multidrug-resistant bacteria.
- Significant knowledge gaps exist concerning the safety and efficacy of phage therapy in clinical settings for IE.
- The review aims to determine if bacteriophage therapy is a realistic treatment option for infective endocarditis.
Conclusions:
- Bacteriophage therapy presents a potential adjunctive strategy for treating infective endocarditis.
- Further preclinical and clinical investigations are essential to establish its role in IE management.
- Addressing safety and efficacy concerns is critical for the clinical adoption of bacteriophage therapy in IE.
Related Concept Videos
01:30Lytic Cycle of Bacteriophages
70.6K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.6K
00:43Lysogenic Cycle of Bacteriophages
62.1K
In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
62.1K